Pruritus: A review

Acta Dermato-Venereologica, Supplement

Volumn , Issue 213, 2003, Pages 5-32

  Weisshaar, Elke ^a,b   Kucenic, Michael J ^a   Fleischer Jr , Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Itch; Mediators of itch; Neurophysiology; Sensation; Skin

Indexed keywords

ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; CAPSAICIN; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DOXEPIN; HETASTARCH; HISTAMINE; METHOXSALEN; MORPHINE; NALFURAFINE; NALMEFENE; NALOXONE; NALTREXONE; NEUROPEPTIDE; OPIATE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PIMECROLIMUS; PROPOFOL; SEROTONIN; STANOZOLOL; TACROLIMUS; THALIDOMIDE; TRAMADOL; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUPUNCTURE; AMYLOIDOSIS; ANAMNESIS; ATOPIC DERMATITIS; BULLOUS SKIN DISEASE; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT DERMATITIS; DISEASE SEVERITY; DROWSINESS; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; GENODERMATOSIS; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRATION; INSECT BITE; LABORATORY TEST; LICHEN PLANUS; MAST CELL; MASTOCYTOSIS; NEURODERMATITIS; NEUROPHYSIOLOGY; NEUROPSYCHIATRY; NONHUMAN; PARAPSORIASIS; PATHOPHYSIOLOGY; PEDICULOSIS; PEMPHIGOID GESTATIONIS; PHOTODERMATOSIS; PHOTOTHERAPY; PITYRIASIS RUBRA PILARIS; PREGNANCY; PRIORITY JOURNAL; PRURIGO; PRURITUS; PSORIASIS; PSYCHOTHERAPY; QUESTIONNAIRE; REVIEW; SCABIES; SCAR; SCRATCHING; SKIN INFECTION; SKIN SENSATION; SKIN TUMOR; TRANSCUTANEOUS NERVE STIMULATION; UREMIA; URTICARIA; XEROSIS; XEROSTOMIA;

FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRURITUS;

EID: 0038522830     PISSN: 03658341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (258)

1. Bernhard JD. Itch: Mechanisms and management of pruritus. McGraw Hill, New York, 1994.
2. Zirwas MJ, Seraly MP. Pruritus of unknown origin: A retrospective study. J Am Acad Dermatol 2001; 45: 892-896.
3. Pujol RM, Gallardo F, Llistosella E, Blanco A, Bernadó L, Bordes R, et al. Invisible mycosis fungoides: A diagnostic challenge. J Am Acad Dermatol 2002; 47: S168-171.
4. Liddell K. Hippocrates of Cos (460-377 BC). Clin Exp Dermatol 2000; 25: 86-88.
5. Hafenreffer S. De pruriti, in Nosodochium, in quo cutis, eiqe adhaerentium partium, affectus omnes, singulari methodo, et cognoscendi et curandi fidelissime traduntur. Ulm, B Kuehn, 1660, 98-102.
6. Dotz W. Jean Paul Marat. His life, cutaneous disease, death, and depiction by Jacques Louis David. Am J Dermpath 1979; 3: 247-250.
7. Appleyard OB. Jean-Paul Marat (1743-1793) - Revolutionary and doctor of medicine. Practitioner 1971; 206: 826-835.
8. Jelinek JE. Jean-Paul Marat - The differential diagnosis of his skin disease. Am J Dermpath 1979; 3: 251-252.
9. Murphy LC. The itches of Jean-Paul Marat. J Am Acad Dermatol 1989; 21: 565-567.
10. Baer RL. Historical overview of the evolution of investigative dermatology (1775-1993). J Invest Dermatol 1994; 103: 3-6.
11. Schmelz M. A neural pathway for itch. Nat Neurosci 2001; 4: 9-10.
12. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001; 4: 72-77.
13. Arthur RP, Shelley WB. The innervation of human epidermis. J Invest Dermatol 1959; 32: 397-411.
14. Dalsgaard CJ, Rydh M, Haegerstrand A. Cutaneous innervation in man visualized with protein gene product 9.5 (PGF 9.5) antibodies. Histochemistry 1989; 92: 385-389.
15. Wang L, Hilliges M, Jernberg T, Wiegleb-Edstrom D, Johannson O. Protein gene product 9.5-immunoreactive nerve fibers and cells in human skin. Cell Tissue Res 1990; 261: 25-33.
16. Kennedy WR, Wendelschafer-Crabb G. The innervation of the human epidermis. J Neurosci 1993; 115: 184-190.
17. Rumio C, Castano P, Veraldi S, Morini M, Castano SM. The innervation of human skin studied with confocal scanning laser microscopy: A comparison between PGP 9.5 immunofluorescence and silver impregnations. Neuroimage 1995; 2: 102-111.
18. Kawakami T, Ishihara M, Mihara M. Distribution density of intraepidermal nerve fibers in normal human skin. J Dermatol 2001; 63-70.
19. Wahlgren CF, Ekblom A. Two-point discrimination of itch in patients with atopic dermatitis and healthy volunteers. Acta Derm Venereol 1996; 76: 48-51.
20. Ruckwied R, Zeck S, Schmelz M, McGlone F. Sensitivity of human scalp investigated by intradermal microdialysis in vivo. J Am Acad Dermatol 2002; 47: 245-250.
21. Schmelz M, Schmid R, Bickel A, Handwerker HO, Torebjörk HE. Specific C-receptors for itch in human skin. J Neurosci 1997; 17: 8003-8008.
22. Ekblom A. Some neurophysiological aspects of itch. Sem Dermatol 1995; 14: 262-270.
23. Hsieh JC, Hägermark Ö, Ståhle-Bäckdahl M, Ericson K, Erikson L, Stone-Elander S, Ingvar M. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 1994; 72: 3004-3008.
24. 2O positron emission tomography studies. Pain 2001; 92: 295-305.
25. Bickford RG. Experiments relating to the itch sensation. Its peripheral mechanisms, and central pathways. Clin Sci 1938; 3: 377-386.
26. Simone DA, Alreja M, LaMotte BH. Psychophysical studies of the itch sensation and itchy skin ("alloknesis") produced by intracutaneous injection of histamine. Somatosens Mot Res 1991; 8: 271-279.
27. Heyer G, Dotzer M, Diepgen TL, Handwerker HO. Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis. Pain 1997; 73: 239-243.
28. Heyer GR, Hornstein OP. Recent studies of cutaneous nociception in atopic and non-atopic subjects. J Dermatol 1999; 26: 77-86.
29. Weisshaar E, Heyer G, Forster C, Hornstein OP, Handwerker HO. Effects of topical antihistamine and topical anaesthetics on iontophoretically induced itch. Hautarzt 1996; 47: 355-360.
30. Weisshaar E, Forster C, Dotzer M, Heyer G. Experimentally induced pruritus and cutaneous reaction with topical antihistamine and local analgesics in atopic eczema. Skin Pharmacol 1997; 10: 183-190.
31. Weisshaar E, Heyer G, Forster C, Handwerker HO. Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. Arch Dermatol Res 1998; 290: 306-311.
32. Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? Inflam Res 1997; 46: 412-416.
33. LaMotte BH. Subpopulations of 'nocifensor neurons' contributing to pain, allodynia and alloknesis. Am Pain Soc J 1992; 1: 115-126.
34. Handwerker HO. Pain and allodynia, itch and alloknesis: an alternative hypothesis. Am Pain Soc J 1992; 1: 135-138.
35. Heyer G, Groene D, Martus P. Efficacy of naltrexone on acetylcholine-induced alloknesis in atopic eczema. Exp Dermatol 2002; 11: 448-455.
36. Bernhard JD, Nonrashes 5. Atmoknesis: Pruritus provoked by contact with air. Cutis 1989; 44: 143-144.
37. Pintér E, Szolcsányi J. Plasma extravasation in the skin and the pelvic organs evoked by antidromic stimulation of the lumbosacral dorsal roots of the rat. Neurosci 1995; 68: 603-614.
38. Schmelz M, Zeck S, Raithel M, Rukwied R. Mast cell tryptase in dermal neurogenic inflammation. Clin Exp Allergy 1999; 29: 695-702.
39. Lewis T, Harris KE, Grant RT. Observations relating to the influence of the cutaneous nerves on various reactions of the cutaneous vessels. Heart 1927; 14: 1-17.
40. Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 2000; 142: 1114-1120.
41. Hägermark Ö. Peripheral and central mediators of itch. Skin Pharmacol 1992; 5: 1-8.
42. Thompsen JS. Itch models and effect of topical antipruritic substances. Forum for Nord Derm Ven 2002; 7(suppl.5):7-42.
43. Fjellner B, Hägermark Ö. Pruritus in polycythaemia: treatment with aspirin and possibility of platelet involvement. Acta Derm Venereol 1979; 59: 505-512.
44. Beck PW, Handwerker HO. Bradykinin and serotonin effects on various types of cutaneous nerve fibers. Pflügers Arch 1974; 347: 209-222.
45. Lischetzki G, Rukwied R, Handwerker HO, Schmelz M. Nociceptor activation and protein extravasation induced by inflammatory mediators in human skin. Eur J Pain 2001; 5: 49-57.
46. Fleischer AB. The clinical management of itching. Parthenon Publishing, New York, London, 2000.
47. Holzer P. Neurogenic vasodilation and plasma leakage in the skin. Gen Pharmacol 1988; 30: 5-11.
48. Scholzen T, Armstrong CA, Bunnett LW, Luger TA, Olerud JE, Ansel JC. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune system. Exp Dermatol 1998; 7: 81-96.
49. Hägermark Ö, Hokfelt T, Pernow B. Flare and itch induced by substance P in human skin. J Invest Dermatol 1978; 71: 233-235.
50. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin - a microdialysis study. J Invest Dermatol 2000; 115: 1015-1020.
51. Henry JL. Substance P and inflammatory pain: potential of substance P antagonists and analgesics. Agents Actions Suppl 1993; 41: 75-87.
52. Osterle LS, Cowen T, Rustin MH. Neuropeptides in the skin of patients with atopic dermatitis. Clin Exp Dermatol 1995; 26: 462-467.
53. Andoh T, Nagasawa T, Satoh M, Kuraishi Y. Substance P induction o fitch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther 1998; 286: 1140-1145.
54. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M, Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002; 147: 71-79.
55. Stander S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of μ-opioid receptor IA on sensory nerve fibers in human skin. Regul Pept 2002; 110: 75-83.
56. Königstein H. Experimental study of itch stimuli in animals. Arch Dermatol Syphiol 1948; 828-849.
57. Feldberg W, Sherwood SL. Injections of drugs into the lateral ventricle of the cat. J Physiol 1954; 123: 148-168.
58. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993; 53: 1253-1257.
59. Yeh HM, Chen LK, Lin CJ, Chan WH, Chen YP, Lin CS, et al. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. Anesth Analg 2000; 91: 172-175.
60. Scott PV, Fischer HBJ. Intraspinal opiates and itching: a new reflex? BMJ 1982; 284: 1015-1016.
61. Milner AR, Bogad DG. Intrathecal administration of morphine for elective cesarean section. Anesthesia 1996; 51: 871-873.
62. Swart M, Sewell J, Thomas D. Intrathecal administration for elective cesarean section: an assessment of pain relief, satisfaction, and side effects. Anesthesia 1997; 52: 373-377.
63. Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, et al. Antipruritic activity of the κ-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002; 435: 259-264.
64. Georgala S, Schulpis KH, Papaconstantinou ED, Stratigos J. Raised beta-endorphin serum levels in children with atopic dermatitis and pruritus. J Dermatol Sci 1994; 8: 125-128.
65. Mettang T, Fischer FP, Dollenbacher U, Kuhlmann U. Uremic pruritus is not related to beta-endorphin serum levels in hemodialysis patients. Nephrol Dial Transplant 1998; 13: 231-232.
66. Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Baillières Clin Gastroenterol 2000; 14: 643-655.
67. DeHaven-Hudkins DL, Cowan A, Cortes Burgos L, Daubert JD, Cassel JA, DeHaven RN, et al. Antipruritic and antihyperalgesic actions of loperamide and analogs. Life Sci 2002; 71: 2787-2796.
68. Wahlgren CF, Scheynius A, Hägermark Ö. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990; 70: 323-329.
69. Wahlgren CF. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy 1992; 47: 65-75.
70. Gaspari AA, Lotze MT, Rosenberg SA, Stem JB, Katz SI. Dermatologic changes associated with interleukin-2 administration. JAMA 1987; 258: 1624-1629.
71. Wahlgren CF, Tengvall Linder M, Hägermark Ö, Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995; 287: 572-580.
72. Darsow U, Scharein E, Bromm B, Ring J. Skin testing in the pruritogenic activity of histamine and the cytokines (interleukin-2 and tumor necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997; 137: 415-417.
73. Lippert U, Hoer A, Möller A, Ramboer I, Cremer B, Henz BM. Role of antigen-induced cytokine release in atopic pruritus. Int Arch Allergy Immunol 1998; 116: 36-39.
74. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17: 1558-1563.
75. Lober C. Should the patient with generalized pruritus be evaluated for malignancy? J Am Acad Dermatol 1988; 19: 350-352.
76. Ståhle-Bäckdahl M. Uremic pruritus: clinical and experimental studies. Acta Derm Venereol 1989; Suppl 145: 1-38.
77. Wahlgren CF, Ekblom A, Hägermark Ö. Some aspects of the experimental induction and measurement of itch. Acta Derm Venereol 1989; 69: 185-189.
78. Melin L, Frederikson T, Noren P, Swebilius BG. Behavioural treatment of scratching in patients with atopic dermatitis. Br J Dermatol 1986; 115: 467-474.
79. Felix R, Shuster S. A new method for the measurement of itch and the response to treatment. Br J Dermatol 1975; 93: 303-312.
80. Ebata T, Iwasaki S, Kamide R, Niimura M. Use of a wrist activity monitor for the measurement of nocturnal scratching in patients with atopic dermatitis. Br J Dermatol 2001; 144: 305-309.
81. Yosipovitch G, Zucker I, Boner G, Gafter U, Shapira Y, David M. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 2001; 81: 108-111.
82. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969-973.
83. Yosipovitch G, Ansari N, Goon A, Chan YH, Goh CL. Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 2002; 147: 32-36.
84. Yosipovitch G, Goon AT, Wee J, Chan YH, Zucker I, Goh CL. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol 2002; 41: 212-216.
85. Darsow U, Mautner VF, Bromm B, Scharein E, Ring J. The Eppendorf Itch Questionnaire. Hautarzt 1997; 48: 730-733.
86. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the "Eppendorf Itch Questionnaire". Int Arch Allergy Immunol 2001; 124: 326-331.
87. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; suppl 92: 44-47.
88. Thestrup-Pedersen K. Clincal aspects of atopic dermatitis. Clin Exp Dermatol 2000; 25: 535-543.
89. Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol 1991; Suppl 165: 4-53.
90. Greaves MW. Antihistamines. Derm Clin 2001; 19: 53-62.
91. Krause L, Shuster S. Mechanism of action of antipruritic drugs. BMJ 1983; 287: 1199-1200.
92. Klein PA, Clarke RAF, An evidence-based review of the efficacy of antihistamine in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135: 1522-1525.
93. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological disease. J Am Acad Dermatol 1999; 41: 533-539.
94. Luger T, Van Leent EJM, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788-794.
95. Reitamo S, Ansul JC, Luger TA. Itch in atopic dermatitis. J Am Acad Dermatol 2001; 45: S 55-56.
96. Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002; 11: 12-24.
97. Barker DJ. Generalized pruritus as the presenting feature of bullous pemphigoid. Br J Dermatol 1983; 109: 237-239.
98. Bingham EA, Burrow D, Sanford JC. Prolonged pruritus and bullous pemphigoid. Clin Exp Dermatol 1984; 9: 564-570.
99. Gupta MA, Gupta AK, Kirby S, Weiner HK, Mace TM, Schork NJ, et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988; 124: 1052-1057.
100. Sehgal VN, Bajaj P, Jain S. Pityriasis rubra pilaris (PRP): report of four cases. J Dermatol 2000; 27: 174-177.
101. Griffith WAD. Pityriasis rubra pilaris: clinical features and natural history in a study of 93 patients. Br J Dermatol 1977; 97 (suppl 15): 18.
102. Accioly-Filho LW, Nogueira A, Ramos-e-Silva M. Prurigo nodularis of Hyde: an update. J Eur Acad Dermatol Venereol 2000; 14: 75-82.
103. Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44: 471-478.
104. Wong SS. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of prurigo nodularis. Arch Dermatol 2000; 136: 807-808.
105. Potasman I, Heinrich I, Bassan HM. Aquagenic pruritus, prevalence and clinical observations. Isr J Med Sci 1990; 26: 499-503.
106. Menage HP, Greaves MW. Aquagenic pruritus. Sem Dermatol 1995; 14: 313-316.
107. Lotti T, Teofoli P, Tsampau D. Treatment of aquagenic pruritus with topical capsaicin cream. J Am Acad Dermatol 1994; 30: 232-335.
108. Moritz DL, Elmets CA. Eosinophilic pustular folliculitis. J Am Acad Dermatol 1991; 24: 903-907.
109. Nagashima M. Prurigo pigmentosa: clinical observation of our 14 cases. J Dermatol 1978; 5: 61-67.
110. Yazawa N, Ihn H, Yemane K, Etoh T, Tamaki K. The successful treatment of prurigo pigmentosa with macrolide antibiotics. Dermatology 2001; 202: 67-69.
111. Schwartz ME. Barn itch. Am Fam Phys 1983; 27: 149-153.
112. Daye S, McHenry JA, Rosceeli JD. Pruritic rash associated with cat scratch disease. Pediatrics 1988; 81: 559-561.
113. Lamberg DI, Green S. Status report of 376 mycosis fungoides patients at 4 years: Mycosis fungoides cooperative group. Cancer Treat Rep 1979; 63: 701-707.
114. Fleischer AB Jr. Pruritus in the elderly. From: Advances in Dermatology, Mosby 1995: 41-59.
115. Malott KR, Stedinger SL. Pruritus. In: Geriatric Dermatology. Igaku-Shoin Medical Publishers, Inc NY, NY 1989: 207-226.
116. Kimyai-Asadi A, Nousari HC, Kimyai-Asadi T, Milani F. Poststroke pruritus. Stroke 1999; 30: 692-693.
117. Daniel GL, Longo WE, Vernava AM. Pruritus ani. Causes and concerns. Dis Colon Rectum 1994; 37: 670-674.
118. Lochridge E. Pruritis ani - perianal psoriasis. South Med J 1969; 62: 450-452.
119. Dasan S, Neill SM, Donaldson DR, Scott HJ. Treatment of persistent pruritus ani in a combined colorectal and dermatological clinic. Br J Surg 1999; 86: 1337-1340.
120. Raddin JB. Pruritus ani, a diagnostic test and indicated medication. Med Times 1961; 89: 687-689.
121. Rumpianski R, Shiskin J. Pruritus vulvae: A five year survey. Dermatologica 1965; 131: 146.
122. Bernhard JD. Macular amyloidosus, notalgia paresthetica and pruritus: Three sides of the same coin? Dermatologica 1991; 183: 53-56.
123. Weinstein BR, Bernhard JD. Incarceration for excoriation. Cutis 1990; 46: 240.
124. Wong TW, Lee JY, Sheu HM, Chao SC. Relief of pain and itch associated with keloids on treatment with oxpentifylline. Br J Dermatol 1999; 140: 771-772.
125. Vitale M, Fields-Blache C, Luterman A. Severe itching in the patients with burns. J Burn Care Rehabil 1991; 12: 330-333.
126. Phillips L, Robson M. Comments from Detroit Receiving Hospital, Detroit, Michigan. J Burn Care Rehabil 1988; 9: 308-309.
127. Bell C, McAdams T, Morgan R, Parshley P, Pike R, Riggs P, Carpenter JE. Pruritus in burns: a descriptive study. J Burn Care Rehabil 1988; 9: 305-308.
128. Matheson JD, Clayton J, Muller MJ. The reduction of itch during burn wound healing. J Burn Care Rehabil 2001; 22: 76-81.
129. Kopecky EA, Jacobson S, Hubley P, Palozzi C, Clarke HM, Koren G. Safety and pharmacokinetic of EMLA in the treatment of postbum pruritus in pediatric patients: A pilot study. J Burn Care Rehabil 2001; 22: 235-242.
130. Gilchrest BA, Stern RS, Steinman TI, Brown R, Arendt K, Anderson W. Clinical features among patients undergoing maintenance hemodialysis. Arch Dermatol 1982; 118: 154-156.
131. Ponticelli C, Bencini PL. Uremic pruritus: A review. Nephron 1992; 60: 1-5.
132. Dimkovic N, Djukanovic L, Radmilavic A, Bojic P, Juloski T. Uremic pruritus and skin mast cells. Nephron 1992; 61: 5-9.
133. Szepietowski J, Thepen T, van Vloten WA, Szepietowski T, Biharia JC. Pruritus and mast cell proliferation in the skin of hemodialysis patients. Inflam Res 1995; 44, suppl 1: S 84-85.
134. Neiman RS, Bischel MD, Lukes RJ. Uremia and mast-cell proliferation. Lancet 1972; 29: 959.
135. Matsumoto M, Ischimaru K, Horie A. Pruritus and mast cell proliferation of the skin in end stage renal failure. Nephron 1985; 23: 285-288.
136. Dallapiccola B, Tataranni G, Farinelli A. Uraemia and mast-cell proliferation. Lancet 1972; 1: 1231.
137. Klein LR, Klein JB, Hanno R, Callen JP. Cutaneous mast cell quantity in pruritic and non-pruritic hemodialysis patients. Int J Dermatol 1988; 27: 557-559.
138. Cohen EP, Russel TJ, Garancis JC. Mast cells and calcium in severe uremic itching. Am J Med Sci 1992; 303: 360-365.
139. Mettang T, Fritz P, Weber J, Machleidt C, Hütel E, Kuhlmann U. Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells. Clin Nephrol 1990; 34: 136-141.
140. DeFilippi C, Regazzini R, Piazza V, Galli F, Pisati P, Sacchi S, Salvadeo A. Uremic pruritus is not related to plasma histamine concentrations. Clin Exp Dermatol 1995; 20: 294-296.
141. Francos GC, Kauh YC, Gittlen SD, Schulman ES, Besarab A, Goyal S, Burke JF. Elevated plasma histamine in chronic uremia. Effects of ketotifen. Int J Dermatol 1991; 30: 884-889.
142. Gill DS, Fonseca VA, Barradas MA, Balliod R, Moorhead JF, Dandona P. Plasma histamine in patients with chronic renal failure and nephrotic syndrome. J Clin Pathol 1991; 44: 243-245.
143. Poignet J, Callebert J, Delons S, Tabuteau F, Chaveau P, Bonete R, et al. Plasma histamine levels and kinetics in chronic hemodialysis patients. ASAIO Trans 1989; 35: 252-254.
144. Stockenhuber F, Kurz RW, Sertl K, Grimm G, Balcke P. Increased plasma histamine levels in uraemic pruritus. Clin Sci 1990; 79: 477-482.
145. DeMarchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E. Relief of pruritus and decrease in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992; 326: 969-974.
146. Piazza V, DeFilippi C, Aprile C, Efficace E, Pisati P, Sacchi S, Salvadeo A. Uremic pruritus and plasma histamine concentration. Nephrol Dial Transplant 1993; 8: 670-671.
147. Weisshaar E, Dunker N, Domröse U, Neumarm KH, Gollnick H. Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy. Clin Nephrol 2003; 59: 124-129.
148. Cho YL, Liu HN, Huang TP, Tarng DC. Uremic pruritus: roles of parathyroid hormone and substance P. J Am Acad Dermatol 1997; 36: 538-543.
149. Yosipovitch G, Reis J, Tur E, Sprecher E, Yamitsky D, Boner G. Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure. Br J Dermatol 1995; 133: 561-564.
150. Kato A, Hamada M, Maruyama T, Maruyama Y, Hishida A. Pruritus and hydration state of stratum corneum in hemodialysis patients. Am J Nephrol 2000; 20: 437-442.
151. Kerr PG, Argiles A, Mion C. Whole blood serotonin levels are markedly elevated in patients on dialytic therapy. Am J Nephrol 1992; 12: 14-18.
152. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystin H. Ondansetron therapy for uremic patients in hemodialysis patients. Am J Kid Dis 2000; 35: 827-831.
153. Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ. A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003; 148: 314-317.
154. Mettang T, Pauli-Magnus C. The pathophysiological puzzle of uremic pruritus - insights and speculations from therapeutic and epidemiological studies. Perit Dial Int 2000; 20: 493-494.
155. Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus an update. Am J Nephrol 2001; 21: 343-350.
156. Pauli-Magnus C, Klumpp S, Alscher DM, Kuhlmann U, Mettang T. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Petit Dial Int 2000; 20: 802-803.
157. Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 1998; 78: 395-402.
158. Silva SRB, Viana PCF, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a cross-over randomized double-blind trial. Nephron 1994; 67: 270-273.
159. Peer G, Kivity S, Agami O, Firemen E, Silverberg D, Blum M, Iaina A. Randomised cross-over trial of naltrexone in uremic pruritus. Lancet 1996; 348: 1552-1554.
160. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11: 514-519.
161. Breneman DC, Cardone JS, Blumsack RF, Lather RM, Searle EA, Pollack VE. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26: 91-94.
162. Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus. A double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 1996; 72: 617-622.
163. Masi CM, Cohen EP. Dialysis efficacy and itching in renal failure. Nephron 1992; 62: 257-261.
164. Cacoub P, Poynard T, Ghillan P, Charlotte P, Olivi M, Piette JC, Opolon P for the Multivirc Group. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999; 42: 2204-2212.
165. Cribier B, Samain F, Vetter D, Heid E, Crosshans E. Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol 1998; 78: 355-357.
166. Cribier B, Santinelli F, Schmitt C, Stoll-Keller F, Grosshans E. Should patients with pruritus be tested for hepatitis C virus infection? A case-controlled study. Br J Dermatol 2000; 142: 1234-1235.
167. Nunes ACR, Amaro P, Maçôas F, Cipriano A, Martins I, Rosa A, et al. Fosinopril-induced prolonged cholestatic jaundice and pruritus: a first case report. Eur J Gastroenterol Hepatol 2001; 13: 279-282.
168. Ryatt KS, Cotteril JA, Littlewood JM. Generalized pruritus in a baby as a presenting feature of the arteriohepatic dysplasia syndrome. Clin Exp Dermatol 1983; 8: 657-661.
169. Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 2000; 14: 33-39.
170. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 355: 657-658.
171. Prince MI, Burt AD, Jones DEJ. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50: 436-439.
172. Berg CI. Use of colesevalem hydrochloride (Welchtol) as a novel therapeutic agent for the management of refractory prutitus in chronic liver disease. Hepatology 2001; 34: 541.
173. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: A double-blind placebo-controlled study. Gastroenterology 1997; 113: 1264-1269.
174. Terg R, Coronel E, Sordá J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002: 37: 717-722.
175. Lewiecki MEM, Rahman F. Pruritus: A manifestation of iron deficiency. JAMA 1976; 236: 2319-2320.
176. Valsecchi R, Cainelli T. Generalized pruritus: A manifestation of iron deficiency. Arch Dermatol 1983; 119: 630.
177. Diehn F, Tefferi A. Pruritus in polycythemia vera: prevalence, laboratory correlates and management. Br J Haematol 2001; 115: 619-621.
178. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002; 99: 2627.
179. Zylicz Z, Krajnik M. Pruritus in cancer: uncommon, but sometimes worse than pain. Ned Tijdschr Geneeskd 1999; 143: 1937-1940.
180. Stefanato CM, Reyes-Mugica M. Masked Hodgkin's disease: The pruriginous disguise. Ped Hematol Oncol 1996; 13: 293-294.
181. Feiner AS, Mahmood T, Wallner S. Prognostic importance of pruritus in Hodgkin's disease. JAMA 1978; 240: 2738-2740.
182. Neilly JB, Martin A, Simpson N, Maccuisk AC. Pruritus in diabetes mellitus: Investigation of prevalence and correlation with diabetes control. Diabetes Care 1986; 9: 273-275.
183. Leylek OA, Unlü S, Oztürkcan S, Cetin A, Sahin M, Yildiz E. Estrogen dermatitis. Eur J Obstr Gynecol 1997; 72: 97-103.
184. Bugatho MJGM, Limbert E, Sobrinho LG, Clode AL, Soares J, Nunes JFM, Conceição Pereira M. A kindred with multiple endocrine neoplasia type 2A associated with pruritic skin lesions. Cancer 1992; 70: 2664-2667.
185. Gelfand JM, Rudikoff D. Evaluation and treatment of itching in HIV-infected patients. Mount Sinai J Med 2001; 68: 298-308.
186. Berger TG, Dhar A. Lichenoid photoeruptions in human immunodeficiency virus infection. Arch Dermatol 1994; 130: 618-623.
187. Milazzo F, Piconi S, Trabattoni D, Magni C, Capetti A, Fusi ML, et al. Intractable pruritus in HIV infection: immunologic characterization. Allergy 2000; 54: 266-272.
188. Lim HW, Vallurupalli S, Meola T, Soter NA. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol 1997; 37: 414-417.
189. Gelfand JM, Rudikoff D, Lebwohl M, Klotman ME. Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: A self-controlled prospective study. Arch Dermatol 1998; 134: 940-945.
190. Bennan B, Flores F, Burke G. Efficacy of pentoxifylline in the treatment of pruritic papular eruption of HIV-infected persons. J Am Acad Dermatol 1998; 38: 955-959.
191. Smith KJ, Skelton HG, Yeager J. Pruritus in HIV 1 disease: Therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology 1997; 195: 353-358.
192. Radomsky LL, Levine N. Thalidomide. Derm Clin 2001; 19: 87-103.
193. Calabrese L, Fleischer AB Jr. Thalidomide: current and potential clinical applications. Am J Med 2000; 108: 487-495.
194. Holmes RC. Polymorphic eruption in pregnancy. Sem Dermatol 1989; 8: 18-22.
195. Aronson IK, Bond S, Fiedler VC, Vomvouras S, Gruber D, Ruiz C. Pruritic urticarial papules and plaques of pregnancy: Clinical and immunopathologic observations in 57 patients. J Am Acad Dermatol 1998; 39: 933-939.
196. Lunzer MR. Jaundice in pregnancy. Bailliėres Clin Gastroenterol 1989; 3: 467-483.
197. Clark TJ, Dwarakanath L, Weaver JB. Pruritus in pregnancy and obstetric cholestasis. Hospital Medicine 1999; 60: 254-260.
198. Riikonen S, Savonius H, Gylling H, Nikkila K, Tuomi AM, Miettinen TA. Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstet Gynecol Scand 2000; 79: 260-264.
199. Kaplan AP. Drug-induced skin disease. J Allergy Clin Immunol 1984; 74: 573-579.
200. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger T. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of a long-term storage in cutaneous nerves. Br J Dermatol 1997; 136: 553-559.
201. Stander S, Bone HG, Machens HG, Aberle T, Burchard W, Prien T, et al. Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 2002; 310: 279-287.
202. Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time related. Br J Anaest 1999; 82: 510-515.
203. Szeimies RM, Stolz W, Wlotzke U, Korting HC, Landthaler M. Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin. Br J Dermatol 1994; 131: 380-382.
204. Koo J, Gambla C. Delusions of parasitosis and other forms of monosymptomatic hypochondriasis. Dermatol Clin 1996; 14: 429-438.
205. Biondi M, Arcangeli T, Petrucci RM. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom 2000; 69:165-166.
206. Fisher DA. Brachioradial pruritus: A recurrent solar dermopathy. JAAD 1999; 41: 656-657.
207. Wallengren J. Brachioradial pruritus: A recurrent solar dermopathy. J Am Acad Dermatol 1998; 39: 803-806.
208. Kavak A, Dosoglu M. Can a spinal tumor cause brachioradial pruritus? J Am Acad Dermatol 2002; 46: 437-440.
209. Wallengren J, Sundler F. Cutaneous field stimulation in the treatment of severe itch. Arch Dermatol 2001; 137: 1323-1325.
210. Astwazaturow M. Über paresthetische Neuralgien und eine besondere Form derselben - Nothalgia paresthetica. Nervenarzt (Berlin) 1934; 133: 88.
211. Savk E, Savk Ö, Bolukbasi O, Culhaci N, Dikicioglu E, Karaman G, Sendur N. Notalgia paresthetica: a study on pathogenesis. Int J Dermatol 2000; 39: 754-759.
212. Wallengren J, Klinher M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, cross-over study. J Am Acad Dermatol 1995; 32: 287-289.
213. Goulden V, Toomey PJ, Higher AS. Successful treatment of notalgia paresthetica with a paravertebral local anesthetic block. J Am Acad Dermatol 1998; 38: 114-116.
214. Drake LA, Fallon JD, Sober A. The Doxepin Study Group. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol 1994; 31: 613-616.
215. Drake LA, Milikan LE. The Doxepin Study Group. The anti-pruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol 1995; 131: 1403-1408.
216. Taylor JS, Praditsuwan P, Handel D, Kuffner G. Allergic contact dermatitis from doxepin cream. One-year patch test clinical experience. Arch Dermatol 1996; 132: 515-18.
217. Nolano M, Simone DA, Wendelschaffer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidemaal nerve fibers and pain sensation. Pain 1999; 81: 135-145.
218. Skaehill PA. Tacrolimus in dermatological disorders. Ann Pharmacother 2001; 35: 582-587.
219. Daly M, Shuster S. Effect of aspirin on pruritus. BMJ 1986; 293: 907.
220. Hägermark Ö. Influence of antihistamines, sedatives, and aspirin on experimental itch. Acta Derm Venereol 1973; 53: 363-368.
221. Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol 2001; 45: 910-913.
222. Zhai H, Hannon W, Hahn GS, Harper RA, Pelosi A, Maibach HI. Strontium nitrate decreased histamine-induced itch magnitude and duration in man. Dermatology 2000; 200: 244-246.
223. Miller MJS, Vergnolle N, McKnight W, Musah RA, Davison CA, Trentacosti AM, et al. Inhibition of neurogenic inflammation by the Amazonian herbal medicine Sangre de Grado. J Invest Dermatol 2001; 117: 725-730.
224. Epstein E, Pinkus JB. A blind study. Arch Dermatol 1964; 89: 548-549.
225. Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Derm Clin 2001; 19: 179-197.
226. Schwörer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61: 33-37.
227. Larijani GE, Golberg ME, Roger KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996; 16: 958-960.
228. Kjellberg F, Tamer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaest 2001; 18: 246-257.
229. Beckwitt Turkel S, Nadala JGB, Wincor MZ. Possible serotonin syndrome in association with 5-HT (3) receptor antagonist agent. Psychosomatics 2001; 42: 258-260.
230. Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain 1997; 71: 49-55.
231. Wallengren J. Cutaneous field stimulation of sensory nerve fibers reduces itch without affecting contact dermatitis. Allergy 2002: 57: 1195-1199.
232. Belgrade MJ, Solomon LM, Lichter EA. Effect of acupuncture on experimentally induced itch. Acta Derm Venereol 1984; 64: 129-133.
233. Ghent CN, Carruther SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, cross-over, randomized trial. Gastroenterol 1988; 94: 488-493.
234. Bergasa NV, Alling DW, Talbot TC, Swain MG, Yurdaydin C, Turner MC, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Am Intern Med 1995; 123: 161-167.
235. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. J Am Acad Dermatol 1999; 41: 431-434.
236. Borgeat A, Wilder-Smith O, Mentha G, Huber O. Propofol and cholestatic pruritus. Am J Gastroenterol 1992; 87: 672-674.
237. McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo-controlled pilot study. J Hepatol 1994; 21: 496-499.
238. Müller C, Pongratz S, Ridlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron. Eur J Gastroenterol Hepatol 1998; 10: 865-870.
239. O'Donohue JW, Haigh C, Williams R. Ondansetron in the treatment of the pruritus of cholestasis: a randomized controlled trial. Gastroenterol 1997; 112: A 1349.
240. Raiford DS. Pruritus of chronic cholestasis. Q J Med 1995; 88: 603-607.
241. Walt RP. Effect of stanozolol on itching in primary biliary cirrhosis. BMJ 1988; 296: 607.
242. Bergasa NV, Link MJ, Keogh M, Yarosloavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001; 96: 1563-1570.
243. Watson CPN, Tyler KL, Bichers SDR, Milikan LE, Smith S, Coleman E. A randomized, vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993; 15: 510-526.
244. The Capsaicin Study Group. Treatment of painful diabetic neuro-pathy with topical capsaicin. Arch Intern Med 1991; 151: 2225-2229.
245. Watson CPN, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomised trial. Pain 1992; 51: 375-379.
246. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986; 15: 504-507.
247. Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz I. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993; 29: 438-442.
248. Jancso G, Lynn B. Possible use of capsaicin in pain therapy. Clin J Pain 1987; 3: 123-126.
249. Reimann S, Luger T, Metze D. Topical capsaicin for the treatment of itch and pain in dermatological patients. Hautarzt 2000; 51: 164-172.
250. Tupker RA, Coenrad PJ, van der Meer JB. Treatment of prurigo nodularis, chronic prurigo and neurodermitis circumscripta with topical capsaicin. Acta Derm Venereol 1992; 72: 463-465.
251. Marks JG. Treatment of apocrine chromhidrosis with topical capsaicin. J Am Acad Dermatol 1989; 21: 418-420.
252. Kirby B, Rogers S. Treatment of PUVA itch with capsaicin. Br J Dermatol 1997; 137: 152.
253. Neess CM, Hinrichs R, Dissemond J, Herrmann G, Poswig A, Servera-Llanras M, et al. Treatment of pruritus by capsaicin in a patient with pityriasis rubra pilaris receiving Re-PUVA therapy. Clin Exp Dermatol 2000; 25: 209-211.
254. Williams LC, Nesbitt LT. Update on systemic glucocorticosteroids in dermatology. Dermatol Clin 2001; 19: 63-77.
255. Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001; 19: 119-137.
256. Daly M, Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol 2000; 80: 24-25.
257. Kjellberg F, Trainer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesth 2001; 18: 346-357.
258. Zylic Z, Smith S, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manag 1998; 16: 121-124.